"The collaboration with Eisai has been very successful and one which I believe has the potential to yield valuable new genetic targets for drug discovery aimed at Alzheimer's disease," said Dr. Tanzi.
About TorreyPines Therapeutics, Inc.
TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel small molecules to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer's disease. Further information is available at http://www.torreypinestherapeutics.com.
This press release contains forward-looking statements or predictions.
Such forward-looking statements include, but are not limited to, statements
regarding the potential for the identification of genes associated with
Alzheimer's disease, the biological validation of genetic targets, and the
possible discovery of therapies to treat Alzheimer's disease. Such
statements are subject to numerous known and unknown risks, uncertainties
and other factors, which may cause TorreyPines' actual results to be
materially different from historical results or from any results expressed
or implied by such forward-looking statements. In particular there is no
guarantee that TorreyPines will be successful in the identification or
validation of genes associated with Alzheimer's disease or the discovery of
therapies to treat Alzheimer's disease, t
|SOURCE TorreyPines Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved